Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Sung Hoon Choi"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Gastrointestinal cancer
ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer
Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Beodeul Kang, Chan Kim, Hyo Sup Shim, Young Nyun Park, Sanghoon Jung, Sung Hoon Choi, Hye Jin Choi, Choong-kun Lee, Hong Jae Chon
Cancer Res Treat. 2023;55(4):1291-1302.   Published online May 3, 2023
DOI: https://doi.org/10.4143/crt.2022.1450
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
There are clinical unmet needs in predicting therapeutic response and precise strategy for the patient with advanced biliary tract cancer (BTC). We aimed to identify genomic alterations predicting therapeutic response and resistance to gemcitabine and cisplatin (Gem/Cis)-based chemotherapy in advanced BTC.
Materials and Methods
Genomic analysis of advanced BTC multi-institutional cohorts was performed using targeted panel sequencing. Genomic alterations were analyzed integrating patients’ clinicopathologic data, including clinical outcomes of Gem/Cis-based therapy. Significance of genetic alterations was validated using clinical next-generation sequencing (NGS) cohorts from public repositories and drug sensitivity data from cancer cell lines.
Results
193 BTC patients from three cancer centers were analyzed. Most frequent genomic alterations were TP53 (55.5%), KRAS (22.8%), ARID1A (10.4%) alterations, and ERBB2 amplification (9.8%). Among 177 patients with BTC receiving Gem/Cis-based chemotherapy, ARID1A alteration was the only independent predictive molecular marker of primary resistance showing disease progression for 1st-line chemotherapy in the multivariate regression model (odds ratio, 3.12; p=0.046). In addition, ARID1A alteration was significantly correlated with inferior progression-free survival on Gem/Cis-based chemotherapy in the overall patient population (p=0.033) and in patients with extrahepatic cholangiocarcinoma (CCA) (p=0.041). External validation using public repository NGS revealed that ARID1A mutation was a significant predictor for poor survival in BTC patients. Investigation of multi-OMICs drug sensitivity data from cancer cell lines revealed that cisplatin-resistance was exclusively observed in ARID1A mutant bile duct cancer cells.
Conclusion
Integrative analysis with genomic alterations and clinical outcomes of the first-line Gem/Cis-based chemotherapy in advanced BTC revealed that patients with ARID1Aalterations showed a significant worse clinical outcome, especially in extrahepatic CCA. Well-designed prospective studies are mandatory to validate the predictive role of ARID1Amutation.

Citations

Citations to this article as recorded by  
  • ARID1A in Gynecologic Precancers and Cancers
    Jaida E. Morgan, Nishah Jaferi, Zainab Shonibare, Gloria S. Huang
    Reproductive Sciences.2024; 31(8): 2150.     CrossRef
  • Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report
    Koji Kameyama, Kosuke Mizutani, Tetsuya Yamada, Seiji Sugiyama, Shingo Kamei, Shigeaki Yokoi, Kengo Matsunaga, Koseki Hirade, Yasutaka Kato, Hiroshi Nishihara, Satoshi Ishihara, Takashi Deguchi
    Molecular and Clinical Oncology.2024;[Epub]     CrossRef
  • A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma
    Wei Zhou, Hao Chi, Xiaohu Zhao, Guangrong Tao, Jianhe Gan
    Clinical and Translational Oncology.2024;[Epub]     CrossRef
  • Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer
    Sohyun Hwang, Seonjeong Woo, Beodeul Kang, Haeyoun Kang, Jung Sun Kim, Sung Hwan Lee, Chang Il Kwon, Dong Soo Kyung, Hwang-Phill Kim, Gwangil Kim, Chan Kim, Hong Jae Chon
    Journal of Hepatology.2024;[Epub]     CrossRef
  • Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors
    Jiumei Zhao, Jing Zhu, Yu Tang, Kepu Zheng, Ziwei Li
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • The role of ARID1A in malignant neoplasms of the female reproductive system: a modern view on diagnostic and therapeutic opportunities
    A. I. Marzaganova, I. R. Martirosyan, A. S. Korchemkina, E. G. Avanesyan, D. A. Korkmazova, O. B. Grakhnova, V. V. Akimina, A. P. Dzhamalutdinova, D. A. Bolloev, A. M. Dugulbgova, Z. G. Bakhmudova, A. T. Salikhova, P. A. Dzigora
    Obstetrics, Gynecology and Reproduction.2024;[Epub]     CrossRef
  • 4,279 View
  • 341 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Case Report
A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
Cancer Res Treat. 2016;48(1):409-414.   Published online February 17, 2015
DOI: https://doi.org/10.4143/crt.2014.299
AbstractAbstract PDFPubReaderePub
von Hippel–Lindau (VHL) disease is an autosomal dominant inherited tumor syndrome associated with mutations of the VHL tumor suppressor gene located on chromosome 3p25. The loss of functional VHL protein contributes to tumorigenesis. This condition is characterized by development of benign and malignant tumors in the central nervous system (CNS) and the internal organs, including kidney, adrenal gland, and pancreas. We herein describe the case of a 74-year-old man carrying the VHL gene mutation who was affected by simultaneous colorectal adenocarcinoma, renal clear cell carcinoma, and hemangioblastomas of CNS.

Citations

Citations to this article as recorded by  
  • Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review
    Yanlei Wang, Zhaoxiang Liu, Wenhui Zhao, Chenxiang Cao, Luqi Xiao, Jianzhong Xiao
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1611.     CrossRef
  • Sporadic Renal Hemangioblastoma: A Case Report of a Rare Entity
    Fnu Raja, Vinesh Kumar, Azzam Hammad, Caroline Abramovich
    Cureus.2023;[Epub]     CrossRef
  • VHL syndrome without clear family history: A rare case report and literature review of Chinese patients
    Yaheng Li, Xiaohong Xin, Wenzhu Song, Xuan Zhang, Shengli Chen, Qian Wang, Aizhong Li, Yafeng Li
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Von Hipple-Lindau disease complicated with central retinal vein occlusion: a case report
    Xingwang Chen, Mengyao Wang, Yuan Tang, Bing Xie, Xiaomei Nie, Shanjun Cai
    BMC Ophthalmology.2022;[Epub]     CrossRef
  • Whole-Exome Sequencing Reveals Novel Variations in Patients with Familial Von Hippel−Lindau Syndrome
    Yuhao Zhou, Jian Liu, Liangzhao Chu, Minghao Dong, Luqian Feng
    World Neurosurgery.2021; 150: e696.     CrossRef
  • Sporadic renal hemangioblastoma: A case report of a rare benign renal tumor
    Lukas Oberhammer, Michael Josef Mitterberger, Lukas Lusuardi, Thomas Kunit, Martin Drerup, Daniela Colleselli, Hubert Griessner, Martina Hager
    Clinical Case Reports.2019; 7(12): 2321.     CrossRef
  • MicroRNA Assisted Gene Regulation in Colorectal Cancer
    Adewale Fadaka, Ashley Pretorius, Ashwil Klein
    International Journal of Molecular Sciences.2019; 20(19): 4899.     CrossRef
  • 13,035 View
  • 102 Download
  • 8 Web of Science
  • 7 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP